Search results for "Rectal Cancer"
showing 10 items of 978 documents
Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (G…
2006
Background Methylation of the p16 promoter is one of the most frequent mechanisms of gene inactivation; its incidence is extremely variable according to the type of tumor involved. Our purpose was to analyze the hypermethylation of the p16 promoter in laryngeal squamous cell carcinomas (LSCC), salivary gland (SG) tumors and in colorectal cancer (CRC), to detect any possible association with the clinicopathological features and to determine the prognostic significance of the p16 gene in the tumors analyzed. Patients and methods The hypermethylation of the p16 promoter was prospectively analyzed, by MSP, in a consecutive series of 64 locally advanced LSCC patients, in a consecutive series of …
Heterogeneity of driver genes and therapeutic implications in colorectal cancer.
2015
455P Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in …
2021
O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C stu…
2021
PD-8 Regorafenib with TAS-102 in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety resu…
2020
Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer
2019
Gene signatures in CRC and liver metastasis
2011
Colorectal cancer (CRC) is one of the most common causes of cancer-related death with a worldwide incidence of almost a million cases annually in both males and females. The accelerated decrease in CRC incidence rates from 1998 to 2006 largely reflects the advances in diagnosis and treatment that have enabled to detect and remove precancerous polyps. However, the screening technology has not resulted in major improvements in the prognosis of patients with advanced cancer and the liver metastasis remains the major cause of death in CRC. About 25% of patients have detectable liver metastasis at diagnosis, that are classified as “synchronous” lesions and approximately 70% of patients develop a…
P021 Heat working environment and risk of breast, chronic lymphocytic leukaemia, colorectal, prostate, and stomach cancer in the MCC-spain case contr…
2016
Occupational exposure to heat can affect the absorption of carcinogenic chemicals into the body, and the metabolism of sexual hormones. We explored the association between occupational exposure to heat and breast, chronic lymphocytic leukaemia, colorectal, prostate, and stomach cancer in the MCC-Spain population based case-control study. Methods The analyses were based on 3047 controls, and 1499 breast, 1539 colorectal, 332 LLC, 1070 prostate, and 382 stomach cancer cases. Heat working environment from either natural or artificial sources was assessed with the MatEmEsp job-exposure matrix. Logistic regression models accounting for education, sex, geographic area, BMI (colorectal, prostate),…
CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2…
2021
Adjuvant colon cancer (CC) therapy and survival have greatly evolved over the last decades. Research shifted towards a more biological tumour understanding and unlocked new therapies and disease mo...
Programmed colorectal cancer screening decreases incidence and mortality
2019
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer- related deaths in the world (1). Detecting and removing precancerous lesions or detecting tumors in early stages through endoscopy decreases CRC mortality (2). Randomized controlled trials (RCTs) have shown that CRC screening based on guaiac fecal occult blood testing (gFOBT) and flexible sigmoidoscopy is effective in reducing incidence and mortality rates of CRC (3).